{
    "root": "85338960-904b-44df-908f-b74b62902779",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CAMZYOS",
    "value": "20250417",
    "ingredients": [
        {
            "name": "MAVACAMTEN",
            "code": "QX45B99R3J",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14921"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "camzyos\u00ae indicated treatment adults symptomatic new york heart association ( nyha ) class ii-iii obstructive hypertrophic cardiomyopathy ( hcm ) improve functional capacity symptoms .",
        "doid_entities": [
            {
                "text": "hypertrophic cardiomyopathy (DOID:11984)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11984"
            },
            {
                "text": "cardiomyopathy (DOID:0050700)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050700"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "must individualized based status echocardiographic assessment patient response . refer full prescribing information instructions . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "camzyos\u00ae supplied immediate release size 2 hard gelatin capsules containing 2.5 mg , 5 mg , 10 mg , 15 mg mavacamten . white opaque capsule bodies imprinted \u201c mava \u201d , opaque cap imprinted strength . capsule contains white off-white powder . camzyos capsules available bottles 30 capsules , listed table : strength capsule cap ndc number 2.5 mg light purple 73625-111-11 5 mg yellow 73625-112-11 10 mg pink 73625-113-11 15 mg gray 73625-114-11 storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) , excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "camzyos contraindicated concomitant : \u2022 strong cyp2c19 inhibitors [ ( 5.2 ) , ( 7.1 ) ] \u2022moderate strong cyp2c19 inducers moderate strong cyp3a4 inducers [ ( 5.2 ) , ( 7.1 ) ]",
    "indications_original": "CAMZYOS\u00ae is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.",
    "contraindications_original": "Dosage must be individualized based on clinical status and echocardiographic assessment of patient response. Refer to the Full Prescribing Information for instructions. ( 2.1 )",
    "warningsAndPrecautions_original": "CAMZYOS\u00ae is supplied as immediate release Size 2 hard gelatin capsules containing 2.5 mg, 5 mg, 10 mg, or 15 mg of mavacamten. White opaque capsule bodies are imprinted with \u201cMava\u201d, and the opaque cap is imprinted with the strength. The capsule contains white to off-white powder. CAMZYOS capsules are available in bottles of 30 capsules, as listed in the table below:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Capsule Cap\n                              \n                           \n                           \n                              \n                                 NDC Number\n                              \n                           \n                        \n                        \n                           \n                              2.5 mg\n                           \n                           \n                              Light purple\n                           \n                           \n                              73625-111-11\n                           \n                        \n                        \n                           \n                              5 mg\n                           \n                           \n                              Yellow\n                           \n                           \n                              73625-112-11\n                           \n                        \n                        \n                           \n                              10 mg\n                           \n                           \n                              Pink\n                           \n                           \n                              73625-113-11\n                           \n                        \n                        \n                           \n                              15 mg\n                           \n                           \n                              Gray\n                           \n                           \n                              73625-114-11\n                           \n                        \n                     \n                  \n                  \n                     Storage \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (between 59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "CAMZYOS is contraindicated with concomitant use of:\n                  \n                     \n                        \u2022\n                        Strong CYP2C19 inhibitors [see \n                        \n                        \n                           Warnings and Precautions (5.2)\n                           , \n                           Drug Interactions (7.1)\n                           ]\n                        \n                     \n                     \n                        \u2022Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers [see Warnings and Precautions (5.2), Drug Interactions (7.1)]",
    "drug": [
        {
            "name": "CAMZYOS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14921"
        }
    ]
}